Pancreatic cancer drug Afinitor by Novartis AG's has been approved by the U.S. FDA for a rare type of pancreatic cancer that has few treatment options, reports Reuters. The Swiss drugmaker said in a statement, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumours (NET) of pancreatic origin."
"This marks the first approval of a treatment for this patient population in the United States in nearly 30 years," they added, Reuters reports.
Pancreatic Cancer Drug Afinitor Approved By FDA
Since September, 16 major drug companies have inked deals with the Trump administration to lower prices....
